Immune responses against Aβ1-42 in HLA class II transgenic mice: Implications for Aβ1-42 immune-mediated therapies

Neurobiology of Aging

Volumn 24, Issue 7, 2003, Pages 969-976

  Das, Pritam ^a   Chapoval, Svetlana ^a   Howard, Victor ^a   David, Chella S ^a   Golde, Todd E ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Alzheimer's disease; A vaccination; A 1 42; MHC class II; Tg2576 mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-42] ANTIBODY; ANTIBODY; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; ANIMAL; ANTIBODY PRODUCTION; C3H MOUSE; C57BL MOUSE; COMPARATIVE STUDY; GENE; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; LYMPHOCYTE; SPECIES DIFFERENCE;

AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODY FORMATION; GENES, MHC CLASS II; IMMUNITY, CELLULAR; IMMUNIZATION; LYMPHOCYTES; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; SPECIES SPECIFICITY;

EID: 0041589303     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(03)00036-8     Document Type: Article

References (29)

1. Abraham R.S., Wen L., Marietta E.V., David C.S. Type 1 diabetes-predisposing MHC alleles influence the selection of glutamic acid decarboxylase (GAD) 65-specific T cells in a transgenic model. J. Immunol. 166(2):2001;1370-1379.
2. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P.et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7(3):2001;369-372.
3. Baisch J.M., Weeks T., Giles R., Hoover M., Stastny P., Capra J.D. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N. Engl. J. Med. 322(26):1990;1836-1841.
4. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H.et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
5. Bell J., Rassenti L., Smoot S., Smith K., Newby C., Hohlfeld R.et al. HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet. 1(8489):1986;1058-1060.
6. Chapoval S.P., Iijima K., Marietta E.V., Smart M.K., Chapoval A.I., Andrews A.G.et al. Allergic inflammatory response to short ragweed allergenic extract in HLA-DQ transgenic mice lacking CD4 gene. J. Immunol. 168(2):2002;890-899.
7. Das P., Bradley D.S., Geluk A., Griffiths M.M., Luthra H.S., David C.S. An HLA-DRB1 × 0402 derived peptide (HV3 65-79) prevents collagen-induced arthritis in HLA-DQ8 transgenic mice. Hum. Immunol. 60(7):1999;575-582.
8. Das P., Drescher K.M., Geluk A., Bradley D.S., Rodriguez M., David C.S. Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis. Hum. Immunol. 61(3):2000;279-289.
9. Das P., Murphy M.P., Younkin L.H., Younkin S.G., Golde T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging. 122(5):2001;721-727.
10. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98(15):2001;8850-8855.
11. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C.et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5(5):2002;452-457.
12. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C.et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
13. Gjertson DW, Geer L, Lee S-H, Kawata J, Sutrisno R. Population studies. In: Terasaki PI, Gjertson DW, editors. HLA 1997. Los Angeles, California: UCLA Tissue Typing Laboratory.
14. Golde T.E., Eckman C.B., Younkin S.G. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochem. Biophys. Acta. 1502:2000;172-187.
15. Ho H.Z., Tiwari J.L., Haile R.W., Terasaki P.I., Morton N.E. HLA-linked and unlinked determinants of multiple sclerosis. Immunogenetics. 15(5):1982;509-517.
16. Hock C., Konietzko U., Papassotiropoulos A., Wollmer A., Streffer J., Von Rotz R.C.et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8(11):2002;1270-1275.
17. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S.et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
18. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D.et al. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
19. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T.et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22(15):2002;6331-6335.
20. Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Desai R.et al. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PDAPP mice. Ann. NY Acad. Sci. 920:2000;328-331.
21. Monsonego A., Maron R., Zota V., Selkoe D.J., Weiner H.L. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98(18):2001;10273-10278.
22. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J.et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
23. Nabozny G.H., Baisch J.M., Cheng S., Cosgrove D., Griffiths M.M., Luthra H.S.et al. HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis. J. Exp. Med. 183(1):1996;27-37.
24. Nepom G.T., Erlich H. MHC class-II molecules and autoimmunity. Annu. Rev. Immunol. 9:1991;493-525.
25. Paisansinsup T., Deshmukh U.S., Chowdhary V.R., Luthra H.S., Fu S.M., David C.S. HLA class II influences the immune response and antibody diversification to Ro60/Sjögren's syndrome-A: heightened antibody responses and epitope spreading in mice expressing HLA-DR molecules. J. Immunol. 168(11):2002;5876-5884.
26. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T.et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
27. 717) mutants. Science. 264:1994;1336-1340.
28. Unanue E.R. Cellular studies on antigen presentation by class II MHC molecules. Curr. Opin. Immunol. 4(1):1992;63-69.
29. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 16:1996;921-932.